open access

Vol 78, No 11 (2007)
ARTICLES
Get Citation

Abnormal second trimester screening for fetal chromosomal abnormalities as a predictor of adverse pregnancy outcome

Elżebieta Baś-Budecka, Małgorzata Perenc, Piotr Sieroszewski
Ginekol Pol 2007;78(11).

open access

Vol 78, No 11 (2007)
ARTICLES

Abstract

Second-trimester maternal serum markers (triple test) is common used to estimate of the fetal risk of genetic abnormalities and open neural tube defects. Positive results of the triple test concomitant with the normal fetus kariotype pattern can also predict the adverse pregnancy outcome. Many authors have been indicated such false positive results of the triple test in the cases of the uterine myomas, PIH, IUGR, and IUD. Objective: The purpose of this study was to determine the association between abnormal second trimester Down syndrome screening markers and adverse pregnancy outcome. Material and Methods: A total of 775 pregnant women underwent maternal serum screening. Pregnancy complications were studied in the groups of pregnancies with structurally and chromosomally normal fetuses – with: elevated AFP>1,89MoM, elevated β-hCG>1,69MoM or low β-hCG<0,48MoM. Results: Increased maternal serum AFP>1,89MoM were found to be significantly associated with IUGR, PIH and placental pathology. Increased β-hCG>1,69MoM were significantly associated with PIH and IUGR. Finally decreased β-hCG<0,48MoM were found to be significantly associated with IUGR, PIH and IUD. Conclusion: Triple test can be used not only for the detection of fetal chromosomal and NTD abnormalities but also for the detection of high-risk pregnancies.

Abstract

Second-trimester maternal serum markers (triple test) is common used to estimate of the fetal risk of genetic abnormalities and open neural tube defects. Positive results of the triple test concomitant with the normal fetus kariotype pattern can also predict the adverse pregnancy outcome. Many authors have been indicated such false positive results of the triple test in the cases of the uterine myomas, PIH, IUGR, and IUD. Objective: The purpose of this study was to determine the association between abnormal second trimester Down syndrome screening markers and adverse pregnancy outcome. Material and Methods: A total of 775 pregnant women underwent maternal serum screening. Pregnancy complications were studied in the groups of pregnancies with structurally and chromosomally normal fetuses – with: elevated AFP>1,89MoM, elevated β-hCG>1,69MoM or low β-hCG<0,48MoM. Results: Increased maternal serum AFP>1,89MoM were found to be significantly associated with IUGR, PIH and placental pathology. Increased β-hCG>1,69MoM were significantly associated with PIH and IUGR. Finally decreased β-hCG<0,48MoM were found to be significantly associated with IUGR, PIH and IUD. Conclusion: Triple test can be used not only for the detection of fetal chromosomal and NTD abnormalities but also for the detection of high-risk pregnancies.
Get Citation

Keywords

Triple Test, false-positive results, adverse pregnancy outcome, biochemical markers

About this article
Title

Abnormal second trimester screening for fetal chromosomal abnormalities as a predictor of adverse pregnancy outcome

Journal

Ginekologia Polska

Issue

Vol 78, No 11 (2007)

Bibliographic record

Ginekol Pol 2007;78(11).

Keywords

Triple Test
false-positive results
adverse pregnancy outcome
biochemical markers

Authors

Elżebieta Baś-Budecka
Małgorzata Perenc
Piotr Sieroszewski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl